Paper Details

  1. Home
  2. Paper Details

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Author: Abd El AzizMohamed, BesirogluBurcu, BorchmannPeter, Caro-ValenzuelaJulia, ErnstMoritz, EstcourtLise J, GoldkuhleMarius, MonsefIna, OeserAnnika, SkoetzNicole

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment option for individuals with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT).
Paper Details　
Original Abstract of the Article :
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of the lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10% are refractory to first-line treatment usually consisting of R-CHOP chemotherapy. Of those eligible for second-line treatment, commonly consisting o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436585/

データ提供：米国国立医学図書館（NLM）

CAR T-cell Therapy: A New Frontier in Diffuse Large B-cell Lymphoma Treatment

This study delves into the complexities of [diffuse large B-cell lymphoma (DLBCL)], a particularly aggressive form of cancer, and explores the promise of [chimeric antigen receptor (CAR) T-cell therapy] as a potentially transformative treatment option. The researchers highlight the challenges faced by individuals with [relapsed or refractory DLBCL], a group with a [very poor prognosis] in the absence of effective treatments. They present [CAR T-cell therapy] as a novel approach that offers a glimmer of hope for these patients.

A New Weapon in the Fight Against Cancer

CAR T-cell therapy represents a revolutionary approach to cancer treatment, harnessing the power of the body's own immune system to fight disease. In this context, the study's findings are especially significant for [individuals who have relapsed or are refractory to conventional therapies] and those who are [ineligible for autologous stem-cell transplantation (ASCT)]. This is akin to discovering a new well in a barren desert, providing a lifeline for those who are desperately seeking sustenance.

Hope for Relapsed and Refractory DLBCL Patients

The potential benefits of CAR T-cell therapy are far-reaching, offering a new avenue for improving the lives of individuals with DLBCL. This approach could lead to [increased remission rates, improved survival, and a better quality of life] for patients who have exhausted other treatment options. Imagine a group of travelers lost in a vast desert, suddenly discovering a hidden oasis, providing refuge and sustenance. This is the promise that CAR T-cell therapy holds for patients with relapsed or refractory DLBCL.

Dr. Camel's Conclusion

This study, like a beacon of light shining through the darkness of a relentless sandstorm, offers hope for patients with relapsed or refractory DLBCL. CAR T-cell therapy represents a groundbreaking advance in cancer treatment, potentially transforming the lives of those who have been left with few options. This research is a testament to the power of innovation and the ongoing quest to conquer even the most challenging medical obstacles.
Date :
  1. Date Completed 2021-11-24
  2. Date Revised 2023-02-16
Further Info :

Pubmed ID

34515338

DOI: Digital Object Identifier

PMC8436585

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.